Benzinga · Sep 18, 2026
‘Crisis of Its Own Creation’: Activist JANA Blasts Cooper, Demands CEO Search
Activist firm Jana Partners calls for leadership overhaul and asset sales at Cooper Companies (COO) amid governance concerns.
NYSE · BLCO
Bausch + Lomb Corporation
Healthcare · Medical - Instruments & Supplies
$17.18
Up+$0.01 (+0.06%)
Updated Oct 7, 2026, 11:29 AM
SID Score
5.2/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 6.12B
- P/E ratio
- -20.07
- Dividend yield
- 0.00%
- 52-week range
- $13.77 – $18.92
- Volume
- 319.7K
- Avg. volume
- 492.22K
Price performance · BLCO
BLCO price history
1M range · 0 trading sessions · Daily adjusted prices
BLCO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest BLCO news
The latest Smart Investors Daily articles mentioning BLCO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BLCO research
Overview
Company profile and research snapshot.
Company profile
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $18.00
- Implied upside
- —
- Analysts
- 20
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | Needham | Hold | — |
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Aug 28, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 30, 2026 | UBS | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 16, 2026
Robinson Pharma, Inc. Receives "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026
Robinson Pharma, Inc. (RPI), a premier full-service contract manufacturer of dietary supplements and nutraceuticals, is proud to announce that it has been honored by Bausch + Lomb with the "Above and Beyond" Supplier Award for the month of September 2026. This prestigious recognition underscores the company's sustained commitment to operational excellence, quality assurance, and the reliable delivery of high-volume manufacturing solutions.
Benzinga · Sep 15, 2026
Bausch + Lomb Receives FDA Warning Letter Over Sterile Drug Manufacturing At Tampa Plant, Citing Inadequate Aseptic Controls And Persistent Microbial Contamination; Products Deemed Adulterated
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bausch-lomb-inc-732398-09042026
Benzinga · Sep 15, 2026
Needham Reiterates Hold on Bausch & Lombto Hold
Needham analyst David Saxon reiterates Bausch & Lomb (NYSE:BLCO) from Hold to Hold.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
